Moderna stock was gaining Tuesday after the vaccination maker announced positive results in a Phase-3 trial for an updated Covid-19 shot.
Moderna said in a news release Tuesday that the company’s “next generation Covid-19 vaccine,” has shown a higher immune response to the virus than the current version of the shot.
The new vaccine evoked…
stock was gaining Tuesday after the vaccination maker announced positive results in a Phase-3 trial for an updated Covid-19 shot.
said in a news release Tuesday that the company’s “next generation Covid-19 vaccine,” has shown a higher immune response to the virus than the current version of the shot.
The new vaccine evoked a stronger immune response to both the Omicron and original strain of Covid-19. This was most notable in people over the age of 65 years old,
said.
The new vaccine also has an improved shelf life, which could “alleviate healthcare provider burden,” the company added.
“mRNA-1283 is a critical component of our combination vaccine against flu and Covid-19, mRNA-1083, and this milestone gives us confidence in our ability to bring this much needed vaccine to market,” Chief Executive Stéphane Bancel said in the release.
Advertisement – Scroll to Continue
Shares of Moderna were rising 1.2% in premarket trading Tuesday to $111.75. Coming into the session, the stock has gained 11% this year.
Write to Angela Palumbo at angela.palumbo@dowjones.com
Discover more from PressNewsAgency
Subscribe to get the latest posts sent to your email.